Print Page    E-mail Page    RSS    E-mail Alerts 

2015 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
11/12/15
Bellerophon Reports 2015 Third Quarter Operational and Financial Results
Phase 3 trial for patients with PAH on track to start enrollment by year-end Special Protocol Assessment (SPA) issued by FDA for Phase 3 program Company plans to continue Phase 2 testing in COPD and initiate clinical testing in Idiopathic Pulmonary Fibrosis (IPF) HAMPTON, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) --  Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported operational and financial results for the third quarter ended September 30, ... 
09/30/15
Bellerophon Announces Functional Respiratory Imaging Data From Company Sponsored Clinical Trial of INOpulse(R) in COPD Patients With Pulmonary Hypertension Presented Today at the European Respiratory Society (ERS) International Congress
HAMPTON, N.J., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced that an oral presentation of late-breaking data from a clinical trial sponsored by the Company was presented today at the European Respiratory Society (ERS) International Congress 2015 in Amsterdam. The data showed that INOpulse®, an inhaled treatment of nitric oxide entering phase 3 testing for the treatment of pulmonary arterial hypertension, impro... 
09/24/15
Bellerophon Therapeutics Announces Positive Data From Interim Analysis of Phase 2 Long-Term Extension Study of INOpulse(R) for Treatment of Pulmonary Arterial Hypertension
Conference Call/Webcast to Be Held September 25, 2015 at 9:00am ET Interim Data Reinforces Earlier Phase 2 Data and Indicates Sustainability of Benefits for PAH Patients FDA Issues a Special Protocol Assessment (SPA) for Phase 3 PAH Program HAMPTON, N.J., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of ... 
09/22/15
Bellerophon Therapeutics - Biotherapeutics Company Developing Therapies to Address Cardiopulmonary and Cardiac Diseases
... 
09/15/15
Bellerophon Therapeutics Announces Leadership Team Changes
- Confirms Focus on Developing INOpulse® Nitric Oxide Therapy for Patients with Pulmonary Hypertension - - Headcount and Costs Substantially Reduced - HAMPTON, N.J., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical stage biotherapeutics company, today announced changes to its leadership team to align with the Company's focus of progressing its nitric oxide therapy program for patients suffering from Pulmonary Hypertension (PH), using Bellerophon... 
09/03/15
Bellerophon to Present in Upcoming Investor Conferences
HAMPTON, N.J., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Chairman and Chief Executive Officer Jonathan Peacock will present at the Rodman and Renshaw Annual Global Investment Conference and participate in the FBR Second Annual Healthcare Conference. Details of the events are as follows: Rodman and Renshaw Annual Global Investment Conference Date: September 10, 2015 Location: St. Reg... 
08/13/15
Bellerophon Reports 2015 Second Quarter Operational and Financial Results
On Track to Initiate Phase 3 Trial for INOpulse(R) in Patients with PAH in the Second Half of 2015 HAMPTON, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported operational and financial results for the second quarter ended June 30, 2015. Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics, commented, "The Company continues to make good progress in bringing forward an imp... 
07/29/15
Bellerophon Therapeutics Expands License Agreement With INO Therapeutics to Develop INOpulse(R) for Three Additional Cardiopulmonary Diseases
License Doubles Potential INOpulse Indications in Product Pipeline HAMPTON, N.J., July 29, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has expanded its license agreement with INO Therapeutics LLC, a division of Mallinckrodt plc (NYSE:MNK), allowing Bellerophon to develop INOpulse® for the treatment of three additional cardiopulmonary diseases, including chronic thromboembolic pulmonary hypertension (CTE... 
07/27/15
Bellerophon Therapeutics Announces Top-Line Results From PRESERVATION I Clinical Trial for Bioabsorbable Cardiac Matrix (BCM)
Management to Hold Conference Call This Morning at 8:30 am ET HAMPTON, N.J., July 27, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical stage biotherapeutics company with programs focused on the treatment of cardiopulmonary and cardiac diseases, today announced top-line results from its PRESERVATION I clinical trial for Bioabsorbable Cardiac Matrix (BCM), an investigational, implantable medical device being studied for the prevention of heart failure following an... 
07/01/15
Bellerophon Therapeutics Announces Management and Board Additions
HAMPTON, N.J., July 1, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointments of Amit Agrawal as Chief Operating Officer, effective July 8, 2015, and Naseem Amin, M.D. as an Independent Director of the Company, effective June 29, 2015. Mr. Agrawal joins Bellerophon from Amgen, Inc., where, since 2012, he served as Director of Strategy and Corporate Development. While at Amgen, Mr. Agrawal worked across... 
05/27/15
Bellerophon Therapeutics Presents Late-Breaking Poster at the European Society of Cardiology's Heart Failure 2015/2nd World Congress on Acute Heart Failure
Positive Data Presented From Bellerophon's Preclinical Study of Bioabsorbable Cardiac Matrix (BCM) Show Reduced Ventricular Remodeling and Increased Ejection Fraction After Heart Attack HAMPTON, N.J., May 27, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced positive results from a recent pig study evaluating the effect of its bioabsorbable cardiac matrix (BCM) product candidate on the mechanics of the heart followin... 
05/20/15
Bellerophon Therapeutics Adds to Experienced Drug and Device Development Management Team
Peter Fernandes Named Vice President and Chief Regulatory Officer HAMPTON, N.J., May 20, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, LLC (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has further strengthened its management team with the addition of Peter Fernandes, as Vice President and Chief Regulatory Officer. Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics, noted, "We are delighted to have Peter join our team an... 
05/15/15
Bellerophon Reports 2015 First Quarter Financial and Operational Results
On Track to Report Top-line BCM Results in Mid-2015 and Initiate Phase 3 Trial in PAH in the Second Half of This Year HAMPTON, N.J., May 15, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the first quarter ended March 31, 2015. "This has been a productive quarter for Bellerophon," said Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. "We completed our ini... 
05/13/15
Bellerophon Therapeutics Appoints Two New Independent Board Members
Appointment Strengthens Cardiovascular and Commercialization Expertise HAMPTON, N.J., May 13, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointments of Scott P. Bruder, M.D., Ph.D. and Scott Huennekens as independent directors. Mr. Huennekens will also serve as a member of the Audit Committee and Dr. Bruder will serve as a member of the Compensation Committee. Jonathan Peacock, Chairman and Chief Exec... 
05/07/15
Bellerophon Therapeutics Forms Scientific Advisory Board for INOpulse(R) Programs
HAMPTON, N.J., May 7, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the formation of an INOpulse® Scientific Advisory Board (SAB) comprised of internationally renowned experts in pulmonary hypertension (PH). The SAB will work closely with Bellerophon's medical team as the Company prepares to advance the development of its proprietary inhaled nitric oxide drug-device combination technology across a range of potenti... 
05/05/15
Bellerophon Therapeutics to Present Late-Breaking Poster at the European Society of Cardiology's Heart Failure 2015/2nd World Congress on Acute Heart Failure
HAMPTON, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will present results from a recent pig study evaluating the effect of its Bioabsorbable Cardiac Matrix (BCM) on the mechanics of the heart following a heart attack. The results will be presented at the Clinical Forum of the European Society of Cardiology's Heart Failure 2015/2nd World Congress on Acute Heart Failure, being held in Seville,... 
03/31/15
Bellerophon Reports 2014 Full Year Financial and Operational Results
HAMPTON, N.J., March 31, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the year ended December 31, 2014. "2014 was an important year for Bellerophon as we established our business, following the spinoff from Ikaria, built our team and achieved several important milestones in our key programs," said Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. "We are ... 
03/25/15
Bellerophon Therapeutics Selects Flextronics to Manufacture the Mark2, Next-Generation INOpulse(R) Device
HAMPTON, N.J., March 25, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has selected Flextronics International Ltd. as its manufacturing partner for the INOpulse® Mark2, the company's next-generation pulsatile nitric oxide delivery device. Bellerophon and Flextronics have entered into an agreement under which Flextronics will manufacture, repair and service the Mark2 devices to be used in Bellerophon's INOp... 
03/16/15
Bellerophon Therapeutics to Ring the NASDAQ Stock Market Closing Bell
HAMPTON, N.J., March 16, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, LLC (Nasdaq:BLPH) a clinical stage biotherapeutics company, today announced that it will preside over the ceremonial NASDAQ Stock Market Closing Bell on Tuesday, March 17, 2015, at 4:00 p.m. ET at the NASDAQ MarketSite in New York City. Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics, will ring the Closing Bell together with members of the senior management team. Mr. Peacock noted, ... 
02/19/15
Bellerophon Therapeutics Announces Closing of Its Initial Public Offering
Hampton, N.J., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) announced today the closing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts. The shares began trading on the NASDAQ Global Market on February 13, 2015 under the ticker symbol "BLPH." Leerink Partners LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. SunTrust Robinson Hum... 
02/13/15
Bellerophon Therapeutics Announces Pricing of Its Initial Public Offering
HAMPTON, N.J., Feb. 13, 2015 /PRNewswire/ -- Bellerophon Therapeutics announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Bellerophon. In addition, Bellerophon has granted the underwriters an option to purchase up to 750,000 additional shares of common stock at the public offering price, less the underwriting discount.  Bell... 
01/29/15
Bellerophon Therapeutics Strengthens Drug and Device Development Capabilities with Key Management Additions
... 
01/04/15
Bellerophon Therapeutics Completes Enrollment in PRESERVATION I, a Trial of Bioabsorbable Cardiac Matrix (BCM) for the Prevention of Congestive Heart Failure After a Heart Attack
...